Pegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B

Kaymakoglu, SABAHATTİN; Oguz, Dilek; Gur, Gurden; Gurel, Selim; Tankurt, Ethem; Ersoz, Galip; Ozenirler, Seren; Kalayci, Cem; Poturoglu, Sule; Cakaloglu, Yılmaz; Okten, Atilla

doi:10.1128/aac.00088-07

Pegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B

Kaymakoglu S., Oguz D., Gur G., Gurel S., Tankurt E., Ersoz G., ...Daha Fazla

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, cilt.51, sa.8, ss.3020-3022, 2007 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 51 Sayı: 8
Basım Tarihi: 2007
Doi Numarası: 10.1128/aac.00088-07
Dergi Adı: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.3020-3022
İstanbul Üniversitesi Adresli: Hayır

Özet

Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of < 400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.